{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:15:36Z","timestamp":1793661336758,"version":"4.5.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Pheochromocytomas are rare neuroendocrine tumors arising from chromaffin cells in the adrenal medulla. They may occur sporadically or in the context of hereditary syndromes. All pheochromocytomas are considered to have malignant potential (defined as risk of metastasis, not local invasion). The use of grading systems with incorporated clinical and histopathologic parameters can help but not definitively predict the metastatic potential of pheochromocytomas. The recent discovery of susceptibility genes provided new insights into the pathogenesis and introduced additional approaches to estimate the metastatic risk of pheochromocytoma. However, the prevalence of these genetic signatures in pheochromocytomas has yet to be fully addressed. Therefore, in the present study, we retrospectively reviewed cases of pheochromocytoma from 1980 to 2018 in the archives of our institution. Three hundred ninety cases were identified, and their clinicopathologic characteristics and genetic statuses were analyzed. About 25% of the cases had metastases, which were more common in older patients (median, 49\u2009y) than in younger ones. Univariate and multivariate analyses revealed that older age, Hispanic ethnicity, metastasis, and large primary tumor size were markedly associated with poor overall survival. In contrast, family history of pheochromocytoma, lack of symptoms, and bilateral adrenal involvement were associated with better survival. About 37% of the pheochromocytomas were associated with inherited syndromes. About 52% of tested patients had pathogenic mutations of pheochromocytoma susceptibility genes. Of these, succinate dehydrogenase B gene mutation had the strongest association with metastasis. These data support that genetic testing should be offered to all patients with pheochromocytoma.<\/jats:p>","DOI":"10.1097\/pas.0000000000001768","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T20:00:41Z","timestamp":1626724841000},"page":"1155-1165","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":27,"title":["Pheochromocytoma"],"prefix":"10.1097","volume":"45","author":[{"given":"Zhonghua","family":"Liu","sequence":"first","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsheng","family":"Ma","sequence":"additional","affiliation":[{"name":"Biostatistics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.path.2019.08.009","article-title":"A guide to pheochromocytomas and paragangliomas","volume":"12","author":"Guilmette","year":"2019","journal-title":"Surg Pathol Clin"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2478\/enr-2019-0020","article-title":"Pheochromocytoma","volume":"53","author":"Farrugia","year":"2019","journal-title":"Endocr Regul"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"T41","DOI":"10.1530\/ERC-19-0435","article-title":"Metastatic pheochromocytoma and paraganglioma: proceedings of the MEN2019 Workshop","volume":"27","author":"Dahia","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/cen.12071","article-title":"Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma","volume":"78","author":"Galan","year":"2013","journal-title":"Clin Endocrinol"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"25756","DOI":"10.18632\/oncotarget.15201","article-title":"Molecular markers of paragangliomas\/ pheochromocytomas","volume":"8","author":"Zhikrivetskaya","year":"2017","journal-title":"Oncotarget"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1210\/jc.2014-2151","article-title":"Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas\/paragangliomas due to succinate dehydrogenase deficiency","volume":"99","author":"Richter","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/modpathol.2015.41","article-title":"SDHB\/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T)","volume":"28","author":"Papathomas","year":"2015","journal-title":"Mod Pathol"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4158\/EP-2017-0057","article-title":"Pheochromocytoma: a genetic and diagnostic update","volume":"24","author":"Mercado-Asis","year":"2018","journal-title":"Endocr Pract"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): a European Network for the Study of Adrenal Tumors Retrospective Study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e318190d12e","article-title":"Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score","volume":"33","author":"Wu","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in pheochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"e0187398","DOI":"10.1371\/journal.pone.0187398","article-title":"Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma","volume":"12","author":"Koh","year":"2017","journal-title":"PLoS One"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/jcm7090242","article-title":"Risk stratification on pheochromocytoma and paraganglioma from laboratory and clinical medicine","volume":"7","author":"Kimura","year":"2018","journal-title":"J Clin Med"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00428-019-02553-5","article-title":"COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas","volume":"474","author":"Pierre","year":"2019","journal-title":"Virchows Arch"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jso.24063","article-title":"Clinical course and prognostic factors in patients with malignant heochromocytoma and paraganglioma: a single institution experience","volume":"112","author":"Choi","year":"2015","journal-title":"J Surg Oncol"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"e0168413","DOI":"10.1371\/journal.pone.0168413","article-title":"Disentangling of malignancy from benign pheochromocytomas\/paragangliomas","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3803\/EnM.2020.35.1.157","article-title":"Epidemiology and prognosis of pheochromocytoma\/paraganglioma in Korea: a nationwide study based on the National Health Insurance Service","volume":"35","author":"Kim","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"R24-20250608","first-page":"590","article-title":"Paragangliomatosis with numerous catecholamine-producing tumors","volume":"57","author":"Karasov","year":"1982","journal-title":"Mayo Clin Proc"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1365-2362.2011.02518.x","article-title":"Metastatic pheochromocytoma: does the size and age matter?","volume":"41","author":"Zelinka","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/EJE-15-0456","article-title":"Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma","volume":"173","author":"Thosani","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2012-4231","article-title":"Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma","volume":"98","author":"Ayala-Ramirez","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.surg.2004.05.058","article-title":"Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas","volume":"136","author":"Shen","year":"2004","journal-title":"Surgery"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40792-016-0214-x","article-title":"Concomitant existence of pheochromocytoma in a patient with multiple endocrine neoplasia type 1","volume":"2","author":"Okada","year":"2016","journal-title":"Surg Case Rep"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-11-0679","article-title":"Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d\u2019etude des Tumeurs Endocrines Database","volume":"166","author":"Gatta-Cherifi","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1210\/jc.2005-2178","article-title":"Review: should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?","volume":"91","author":"Jimenez","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.292.8.943","article-title":"Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations","volume":"292","author":"Neumann","year":"2004","journal-title":"JAMA"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"E805","DOI":"10.1210\/jc.2011-3360","article-title":"TMEM127 screening in a large cohort of patients with pheochromocytoma and\/or paraganglioma","volume":"97","author":"Abermil","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-20250608","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1001\/jama.2010.1830","article-title":"Spectrum and prevalence of FP\/TMEM127 gene mutations in pheochromocytomas and paragangliomas","volume":"304","author":"Yao","year":"2010","journal-title":"JAMA"},{"key":"R35-20250608","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ng.861","article-title":"Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma","volume":"43","author":"Comino-Mendez","year":"2011","journal-title":"Nat Genet"},{"key":"R36-20250608","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","article-title":"MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma","volume":"18","author":"Burnichon","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R37-20250608","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1469-1809.2007.00396.x","article-title":"Evidence for a founder effect of the germline fumarate hydratase gene mutation R58P causing hereditary leiomyomatosis and renal cell cancer (HLRCC)","volume":"72","author":"Heinritz","year":"2008","journal-title":"Ann Hum Genet"},{"key":"R38-20250608","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"key":"R39-20250608","doi-asserted-by":"crossref","first-page":"E2046","DOI":"10.1210\/jc.2014-1659","article-title":"Germline FH mutations presenting with pheochromocytoma","volume":"99","author":"Clark","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T17:06:25Z","timestamp":1749402385000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001768"}},"subtitle":["A Clinicopathologic and Molecular Study of 390 Cases From a Single Center"],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001768","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740500289.793588370","asserted-by":"object"}]},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,19]]}}}